The Long Run with Luke Timmerman

Afleveringen

• 
  Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases 28.07.2026 1u 7min

  Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
• 
  Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With 14.07.2026 1u 8min

  Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
• 
  Ep204: Troy Wilson on Precision Cancer Drugs and Combos 30.06.2026 1u 7min

  Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
• 
  Ep203: Sri Kosuri on Small Molecule Correctors of Disease 16.06.2026 1u 11min

  Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
• 
  Ep202: Becky Pferdehirt on Reimagining Science for the AI Era 02.06.2026 1u 8min

  Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
• 
  Ep201: Jeremy Levin on Biotech in the Balance 19.05.2026 1u 8min

  Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
• 
  Ep200: Richard Pops Reflects on a 35-Year Career in Biotech 05.05.2026 1u 13min

  Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
• 
  Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era 21.04.2026 1u 10min

  Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
• 
  Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery 07.04.2026 1u 16min

  Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
• 
  Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature 31.03.2026 1u 16min

  Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
• 
  Ep196: Otello Stampacchia on Europe's Biotech Crisis 17.03.2026 1u 3min

  Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
• 
  Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases 03.03.2026 1u 5min

  Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
• 
  Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery 17.02.2026 1u 8min

  Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
• 
  Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines 22.01.2026 1u 5min

  Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
• 
  Ep192: Kate Haviland on Following the Science to Precision Immunology 08.01.2026 1u 26min

  Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
• 
  Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease 15.12.2025 1u 7min

  Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
• 
  Ep190: Neil Kumar on Building a Rare Disease Drug Company 20.11.2025 1u 13min

  Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
• 
  Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI 12.11.2025 1u 12min

  Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
• 
  Ep188: Art Krieg on Innate Immune System Activators for Cancer 28.10.2025 1u 9min

  Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
• 
  Ep187: Eric Fischer on Creating a New Class of Medicines 14.10.2025 1u 5min

  Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.